Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Phase 2 Terminated 93 enrolled Shanghai Pulmonary Hospital, Shanghai, China

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant PD-1 antibody plus chemotherapy followed by surgery in resectable stage IIIA-N2 non-small cell lung cancer.

Timeline

Start: 2020-07-13
Primary completion: 2022-09-30
Completion: 2022-09-30

Outcome

Outcome not reported

Stopped (Enrollment): “since the CheckMate816 study is published in NEJM, enrolling patients becomes difficult”

Publications

Xu L, Si H, Zhuang F, Li C, Zhang L, Zhao Y, Chen T, Dong Y, Wang T, Hou L, Hu T, Sun T, She Y, Hu X, Xie D, Wu J, Wu C, Zhao D, Chen C. Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg. 2025 Jan;169(1):242-253.e4. doi: 10.1016/j.jtcvs.2024.05.006. Epub 2024 May 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Carboplatin	Small molecule	—	Intravenous
Background	Nab-paclitaxel	Small molecule	—	Intravenous
Background	Pemetrexed	Small molecule	—	Intravenous